Merck & Company Inc (MRK)vsOrchestra BioMed Holdings Inc. (OBIO)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
OBIO
Orchestra BioMed Holdings Inc.
$6.12
+5.34%
HEALTHCARE · Cap: $305.33M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 208084% more annual revenue ($66.57B vs $31.98M). MRK leads profitability with a 4.8% profit margin vs -184.6%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
OBIO
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Intrinsic value data unavailable for OBIO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Trading at 19.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -107.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : OBIO
OBIO has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : OBIO
The primary concerns for OBIO are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.41 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while OBIO is a turnaround play — different risk/reward profiles.
OBIO carries more volatility with a beta of 0.53 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 15/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Orchestra BioMed Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?